Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wuxi Biologics Cayman Inc ADR (OP:WXXWY)

5.850 +0.100 (+1.74%)
Streaming Delayed Price Updated: 3:17 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,230
Open 5.875
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 5.750
Today's Range 5.810 - 5.875
52wk Range 2.580 - 7.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs. 
Via Benzinga
Topics Government
Exposures Political
Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront
Curon Biopharmaceutical, a Shanghai company, out-licensed global rights for a clinical-stage bispecific candidate to Merck (MSD) for $700 million upfront plus $600 million in milestones. 
Via Talk Markets

Performance

YTD
+36.7%
+36.7%
1 Month
+19.6%
+19.6%
3 Month
+5.4%
+5.4%
6 Month
+39.0%
+39.0%
1 Year
+47.7%
+47.7%

More News

Read More
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Via Talk Markets
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
Via Benzinga
Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement
Via Talk Markets
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Via Talk Markets
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Via Talk Markets
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Via Talk Markets
Strong Consumer Turnout Drives Hong Kong Stocks Higher Friday As China's Former Premier Li Keqiang Dies At 68
Via Benzinga
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
Via Talk Markets
Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact
Via Talk Markets
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion
Via Talk Markets
Wuxi Biologics Will Be Removed From U.S. Commerce Department's ‘Unverified List’
Via Talk Markets

Frequently Asked Questions

Is Wuxi Biologics Cayman Inc ADR publicly traded?
Yes, Wuxi Biologics Cayman Inc ADR is publicly traded.
What exchange does Wuxi Biologics Cayman Inc ADR trade on?
Wuxi Biologics Cayman Inc ADR trades on the OTC Traded
What is the ticker symbol for Wuxi Biologics Cayman Inc ADR?
The ticker symbol for Wuxi Biologics Cayman Inc ADR is WXXWY on the OTC Traded
What is the current price of Wuxi Biologics Cayman Inc ADR?
The current price of Wuxi Biologics Cayman Inc ADR is 5.850
When was Wuxi Biologics Cayman Inc ADR last traded?
The last trade of Wuxi Biologics Cayman Inc ADR was at 05/09/25 03:17 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.